12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ixmyelocel-T: Phase III discontinued

Aastrom said it will no longer develop its only product, ixmyelocel-T, to treat CLI and will instead focus R&D resources on developing the product for dilated cardiomyopathy (DCM). The company terminated the double-blind, placebo-controlled, U.S. Phase III REVIVE trial evaluating intramuscular ixmyelocel-T to treat CLI based on "enrollment challenges" and the determination that the program would "not be supported by a partner...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >